Skip to content

Reverse HFpEF: Ketogenic Reversal of Heart Failure With Preserved Ejection Fraction Study

Reverse HFpEF: Ketogenic Reversal of Heart Failure With Preserved Ejection Fraction Study

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04942548
Enrollment
16
Registered
2021-06-28
Start date
2019-07-25
Completion date
2023-07-24
Last updated
2024-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart Failure

Keywords

obese, keto, diet, cardiac

Brief summary

This protocol is a prospective pilot study utilizing the intervention of a medically supervised, registered nurse and registered diabetes educator coached low-carbohydrate, ketogenic diet to examine the impact it has as a treatment for heart failure with preserved ejection fraction.

Interventions

OTHERKetogenic Diet

Ketogenic diet intervention that is high in fat and low in carbohydrates, causing the body to induce a state of metabolic ketosis, whereby fat is broken down into ketones to provide an energy source for the body.

Sponsors

National Jewish Health
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
21 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Adults (age 21-80) who meet clinical signs and symptoms of heart failure based on clinical assessment. * The subject must meet at least one of the following hemodynamic criteria for HFpEF of PH-HFpEF by right heart catheterization (RHC) within 6 months of screening visit; A) HFpEF: 1. At rest: mean pulmonary artery occlusions pressure (PAOP) \> 15, pulmonary vascular resistance (PVR) \< 3 Wood Units, or 2. HFpEF with fluid challenge, defined as increase in PAOP post 500 cc fluid bolus: mean PAOP \> 18, PVR \< 3 Wood Units, or 3. HFpEF with exercise, defined as peak mean PAOP \> 17, PVR \< 3 Wood Units if age \< 50 or peak mean PAOP \> 19 and PVR \< 3 Wood Units if age \>= 50 B) PH-HFpEF: 1. At rest: mean pulmonary artery occlusion pressure (PAOP) \> 15, mean pulmonary artery pressure (PAP) \>= 25, pulmonary vascular resistance (PVR) \> 3 Wood Units, or 2. PH-HFpEF with fluid challenge, defined as increase in PAOP post 500 cc fluid bolus: mean PAOP \> 18, mean PAP \>= 25, PVR \> 3 Wood Units, or 3. PH-HFpEF with exercise, defined as peak mean PAOP \> 17, peak mean PAP \> 30, peak PVR \> 1.34 Wood Units if age \< 50 or peak mean PAOP \> 19, peak mean PAP \> 33, and PVR \< 2.1 Wood Units if age \>= 50 * The subject also must meet criteria for metabolic syndrome, defined as: Abdominal obesity (BMI \> 30 kg/m2 or abdominal obesity, waist circumference \> 102 cm men, \> 88 cm women) AND 2 of the following; a. Currently being treated for systemic hypertension or blood pressure (BP) \>= 135/85 b. Glucose intolerance with diagnosis of type 2 diabetes, or fasting blood glucose 110-125 mg/dL or hemoglobin A1c \> 6% c. Triglycerides \>= 150, or on treatment for high triglycerides d. HDL \< 40 men, \< 50 women, or on treatment for high triglycerides * If the subject is on pulmonary hypertension specific vasodilators, they must be on stable medical therapy without changes to pulmonary vasodilator medication within 3 months prior to screening visit. * The subject must have also had a cardiopulmonary exercise test within 6 months of screening visit. * The subject must have also had an echocardiogram within 6 months of screening visit. * The subject must have demonstrated stable weight (less that 5% weight loss) 3 months prior to screening visit. (They cannot already be losing weight). * The subject owns and uses a smartphone or tablet. * Must speak English

Exclusion criteria

* The subject is already on a significant weight loss trajectory prior to study entry. * The subject cannot be on an alternative diet plan or strategy (e.g., Weight Watchers, Nutrisystem, Ornish). * Left ventricular ejection fraction \< 50%. * Severe valvular disease by echocardiogram or dysfunctional prosthetic valve. * Active pericardial disease (moderate or large pericardial effusion or constrictive pericarditis). * Active coronary ischemia defined by abnormal stress test, angiogram, or coronary CT angiography per investigator. * Prolonged corrected QT interval (QTc) \> 450 ms * Significant lung disease on pulmonary function tests (PFT's) within the 6 months of screening visit, (Both post-bronchodilator values and pre-bronchodilator values must meet

Design outcomes

Primary

MeasureTime frameDescription
MLHFQ Questionnaire6 MonthsChange in score on the Minnesota Living with Heart Failure Quality of Life (MLHFQ) Questionnaire for the HFpEF cohort. * Max. Score = 105 * Min. Score = 0 * A reduced score means improvement of heart failure symptoms; better outcome
PAH-SYMPACT Questionnaire6 MonthsChange in score on the Pulmonary Arterial Hypertension-Symptoms and Impact (PAH-SYMPACT) Questionnaire for the PH-HFpEF cohort. * Max. Score = 89 * Min. Score = 0 * A reduced score means improvement of pulmonary hypertension heart failure symptoms; better outcome

Secondary

MeasureTime frameDescription
Change in Metabolic Health: Insulin6 MonthsInsulin in microinternational unit per milliliter (uIU/mL)
Change in Metabolic Health: Homeostatic Model Assessment for Insulin Resistance (HOMA-IR)6 MonthsInsulin and glucose are multiplied then divided by 405 to report HOMA-IR
Change in Metabolic Health: Albumin6 MonthsAlbumin in grams per deciliter (g/dL)
Change in Metabolic Health: Bilirubin total6 MonthsBilirubin total in milligrams per deciliter (mg/dL)
Change in Metabolic Health: Alanine Transaminase (ALT)6 MonthsALT in units per liter (U/L)
Change in Metabolic Health: Aspartate Aminotransferase (AST)6 MonthsAST in units per liter (U/L)
Change in Metabolic Health: Alkaline Phosphatase (ALP)6 MonthsALP in units per liter (U/L)
Change in Metabolic Health: High Sensitivity C-Reactive Protein (HS-CRP)6 MonthsHS-CRP in milligrams per deciliter (mg/dL)
Change in Metabolic Health: Triglycerides6 Monthstriglyceride in milligrams per deciliter (mg/dL)
Change in Metabolic Health: High Density Lipoprotein (HDL)6 MonthsHDL in milligrams per deciliter (mg/dL)
Change in Metabolic Health: Hemoglobin A1c6 Monthshemoglobin A1c in percent (%)
Change in Metabolic Health: Body Mass Index (BMI)6 MonthsWeight and height will be combined to report BMI in kg/m\^2
Changes in Physical Function: 6 Minute Walk Test (6MWT)6 Months6-minute walk test is reported in meters (m) of how far a subject walks in 6 minutes
Changes in Physical Function: Maximum Oxygen Consumption (VO2max)6 MonthsVO2 max is reported in liters per minute (L/min) while performing a cardiopulmonary exercise test (CPET)
Changes in Physical Function: Maximum Work6 MonthsMaximum work achieved while performing a cardiopulmonary exercise test (CPET) is reported in watts (W)
Changes in Physical Function: 30 Second Sit-to-Stand test (30s STS)6 Months30s STS is reported in quantity of how many times the subject can come to a full stand from a seated position in 30 seconds (s)
Changes in Physical Function: Leg Press - 1 Repetition Maximum6 MonthsLeg press is reported in kilograms (kg)
Change in Metabolic Health: Weight6 MonthsWeight in kilograms (kg)
Changes in Physical Function: Leg Extension - 1 Repetition Maximum6 MonthsLeg extension is reported in kilograms (kg)
Cardiac Remodeling: Changes in the Left Ventricle (LV) size6 MonthsThis is determined by the internal diameter measurement of the LV, reported in centimeters (cm) from a subject performed echocardiogram
Cardiac Remodeling: Changes in the Left Ventricle (LV) thickness6 MonthsThis is determined by a measurement of the LV wall, reported in millimeters (mm) from an echocardiogram.
Cardiac Remodeling: Changes in the Left Ventricle (LV) mass6 MonthsThis is determined by a combination formula of the interventricular septum diastole (IVSd), left ventricle diastole (LVd), and posterior wall diastole (PWd), calculated by an echocardiogram and reported in grams (g).
Cardiac Remodeling: Changes in Left Atrium (LA) size6 MonthsThis is determined by the internal diameter measurement of the LA, reported in centimeters (cm) from a subject performed echocardiogram.
Cardiac Remodeling: Changes in Inferior Vena Cava (IVC) size6 MonthsThis is determined by the internal diameter perpendicular to the long axis of the IVC at the end-expiration, reported in centimeters (cm) from the echocardiogram.
Cardiac Remodeling: Changes in estimated Right Atrial Pressure (RAP)6 MonthsThis is determined by a combination equation subtracting the venous return (VR) from the central venous pressure (CVP), reported in millimeters of mercury (mmHg) from the echocardiogram.
Cardiac Remodeling: Changes in Right Ventricle Systolic Pressure (RVSP)6 MonthsThis estimates the pressure inside the artery that supplies the lung with blood, reported in millimeters of mercury (mmHg) from the echocardiogram.
Changes in the rate of mitral annulus velocity (e')6 Monthse' is reported in centimeters per second (cm/s) based on a subject performed echocardiogram
Changes in the ratio of transmitral early peak velocity (E) by pulsed wave Doppler over e' (E/e')6 MonthsE/e' is reported as an integer based on the transmitral early peak velocity (E) over the mitral annulus velocity (e') from a subject performed echocardiogram.
PH-HFpEF Only Hemodynamics: Changes in Right Atrial Pressure (RAP)6 MonthsThis is determined by a combination equation subtracting the venous return (VR) from the central venous pressure (CVP), reported in millimeters of mercury (mmHg) from the echocardiogram.
PH-HFpEF Only Hemodynamics: Changes in Pulmonary Artery Pressure (PAP)6 MonthsThis is calculated from systolic, by Tricuspid Regurgitation maximum (TRmax) and diastolic, by Pulmonary Regurgitation-end velocity (PR-end) pulmonary artery pressures, reported in millimeters of mercury (mmHg) from the echocardiogram.
PH-HFpEF Only Hemodynamics: Changes in Pulmonary Artery Occlusive Pressure (PAOP)6 MonthsThis is determined by the pressure value of the pulmonary artery once it's occluded during a Right Heart Catheterization (RHC), measured in millimeters of mercury (mmHg).
PH-HFpEF Only Hemodynamics: Changes in Pulmonary Vascular Resistance (PVR)6 MonthsLeft Atrial Pressure (LAP), Pulmonary Artery Pressure (PAP) and Cardiac Output (CO) are combined to report the PVR in Wood Units (WU) from a Right Heart Catheterization (RHC).
PH-HFpEF Only Hemodynamics: Changes in Cardiac Output (CO)6 MonthsStoke Volume (SV) and Heart Rate (HR) are combined to report CO in liters per minute (L/min) from the right heart catheterization.
PH-HFpEF Only Hemodynamics: Changes in Cardiac Index (CI)6 MonthsCardiac Output (CO) and Body Surface Area (BSA) are combined to report CI in liters per minute per meters squared (L/min/m\^2) from a Right Heart Catherization (RHC).
Changes in Physical Function: Chest Press - 1 Repetition Maximum6 MonthsChest press is reported in kilograms (kg)
Change in Metabolic Health: Glucose6 MonthsGlucose in milligrams per deciliter (mg/dL)

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026